ROSGQ (Rosetta Genomics) ROE % Adjusted to Book Value: -60.15% (As of Jun. 2017)


What is Rosetta Genomics ROE % Adjusted to Book Value?

Rosetta Genomics ROSGQ -99.00% ROE % Adjusted to Book Value is -60.15% as of Jun. 2017.

Rosetta Genomics's ROE % for the quarter that ended in Jun. 2017 was -332.63%. Rosetta Genomics's PB Ratio for the quarter that ended in Jun. 2017 was 5.53. Rosetta Genomics's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2017 was -60.15%.

Rosetta Genomics ROE % Adjusted to Book Value Related Terms

Rosetta Genomics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Rosetta Genomics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rosetta Genomics ROE % Adjusted to Book Value Chart

Rosetta Genomics Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -50.35 -36.67 -42.65 -77.53 -64.32

Rosetta Genomics Semi-Annual Data
Dec07 Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -30.92 -83.79 -48.47 -98.25 -60.15

ROSGQ vs TEAR, IDTA, ABMC: ROE % Adjusted to Book Value Comparison

For the Diagnostics & Research subindustry, Rosetta Genomics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rosetta Genomics ROE % Adjusted to Book Value vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Rosetta Genomics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Rosetta Genomics's ROE % Adjusted to Book Value falls into.


Rosetta Genomics ROE % Adjusted to Book Value Calculation

Rosetta Genomics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2016 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-135.07% / 2.10
=-64.32%

Rosetta Genomics's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2017 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-332.63% / 5.53
=-60.15%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -60.15% mean?
Rosetta Genomics (ROSGQ) has a ROE % Adjusted to Book Value of -60.15% as of Jun. 2017. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Rosetta Genomics and its competitors.
Is Rosetta Genomics' ROE % Adjusted to Book Value too high?
Rosetta Genomics' current ROE % Adjusted to Book Value is -60.15%.
How does Rosetta Genomics' ROE % Adjusted to Book Value compare to TEAR and IDTA?
Rosetta Genomics' ROE % Adjusted to Book Value of -60.15% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Diagnostics & Research company?
A good ROE % Adjusted to Book Value depends on the Medical Diagnostics & Research industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Rosetta Genomics and its competitors. Rosetta Genomics's current ROE % Adjusted to Book Value is -60.15%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rosetta Genomics stock overvalued right now?
Rosetta Genomics (ROSGQ) has a current ROE % Adjusted to Book Value of -60.15%. The current ROE % Adjusted to Book Value is -60.15%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Rosetta Genomics (ROSGQ), the current ROE % Adjusted to Book Value is -60.15% as of Jun. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rosetta Genomics Business Description

Address 10 Plaut Street, Science Park, Rehovot, ISR, 76706
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.